|
|
Post by hellodolly on Apr 12, 2021 7:03:55 GMT -5
Man, this was a good read. Some funny chit. I'm glad the days of MNKD going bankrupt are behind us now and we've moved onto concerns of compensation. That's a remarkable turnaround if you think about both of them...tied to money. One projects a company as a sure failure, the other projects flashes of success. Yes, they are not necessarily mutually exclusive however, it's something to laugh about on social media boards filled with imposters, pretenders and shills. The ink trail they leave behind is written on paper reserved for the restroom.
I'm pretty sure there's some sort of 'compensation committee' that defines the various targets and incentives, along with the award, that the CEO is measured against. The classic question that always comes up in these 'pay for performance' based compensation concerns by shareholders is, "Did the compensation committee set the benchmarks too low?" or, "Did the CEO overachieve?" and finally, "Could it be both?" Hard to say not being a part of the team but, from what I read it seems that the results were quantitative, as there should be some sort of measured accountability.
I'm not in either camp on the issue, but the camp I'm in is the one that looks at SP. I've seen it drop below $1 and I currently see it hovering around $4, a trend in the right direction and no matter if you're still upside down or have your head above water, a trend in the right direction is something you don't easily dismiss when it comes to compensation. When I read that people are unhappy with compensation, I ask if the concerns are justified or not? In this case, everyone has an opinion and I have mine.
UBER BULLISH
|
|
|
|
Post by goyocafe on Apr 13, 2021 2:39:14 GMT -5
Man, this was a good read. Some funny chit. I'm glad the days of MNKD going bankrupt are behind us now and we've moved onto concerns of compensation. That's a remarkable turnaround if you think about both of them...tied to money. One projects a company as a sure failure, the other projects flashes of success. Yes, they are not necessarily mutually exclusive however, it's something to laugh about on social media boards filled with imposters, pretenders and shills. The ink trail they leave behind is written on paper reserved for the restroom. I'm pretty sure there's some sort of 'compensation committee' that defines the various targets and incentives, along with the award, that the CEO is measured against. The classic question that always comes up in these 'pay for performance' based compensation concerns by shareholders is, "Did the compensation committee set the benchmarks too low?" or, "Did the CEO overachieve?" and finally, "Could it be both?" Hard to say not being a part of the team but, from what I read it seems that the results were quantitative, as there should be some sort of measured accountability. I'm not in either camp on the issue, but the camp I'm in is the one that looks at SP. I've seen it drop below $1 and I currently see it hovering around $4, a trend in the right direction and no matter if you're still upside down or have your head above water, a trend in the right direction is something you don't easily dismiss when it comes to compensation. When I read that people are unhappy with compensation, I ask if the concerns are justified or not? In this case, everyone has an opinion and I have mine. UBER BULLISH The wise saying that ends in “depth perception” fits well to summarize my feelings about executive compensation. After all, anyone sitting on MNKD at $1.20 is probably licking their chops at the potential going forward. Whereas the dudes and dudettes still waiting to recover their initial investment cost see the same performance as just a beginning. |
|
|
|
Post by buyitonsale on Apr 14, 2021 14:11:52 GMT -5
Just voted.
For All
For
Against
I have gone through all the compensation materials in the proxy and yes, it is based on market research, but from my perspective, as a shareholder, I feel that shareholders still need to get paid first and the management second.
Especially the long term shareholders that have gone thought RS and held on for all this time since 2014 and earlier.
Once the company becomes profitable and Afrezza gets the market share it deserves, I will have no problems voting "For" any market based compensation package they propose.
Having said this, I think that CEO is not going anywhere and is committed to increasing shareholder value that has been long overdue, with or without the compensation package approval...
|
|
|
|
Post by sportsrancho on Apr 14, 2021 14:30:43 GMT -5
Same
|
|
|
|
Post by longliner on Apr 15, 2021 15:41:17 GMT -5
As long term MNKD shareholders I believe there is a little Missourian in each of us...I am reserving my vote for compensation until we get clarity on how shareholders benefit from the sale leaseback of the Danbury Facility and for UTHR to confirm submission of the Priority Review Voucher.
|
|
|
|
Post by mytakeonit on Apr 15, 2021 15:55:48 GMT -5
From what I've seen MNKD and company doing ... I don't have a problem voting "For" on all counts.
But, that's mytakeonit
|
|
|
|
Post by longliner on Apr 15, 2021 16:21:28 GMT -5
From what I've seen MNKD and company doing ... I don't have a problem voting "For" on all counts. But, that's mytakeonit We do have plenty of excitement on the immediate horizon. We have been here for many exciting horizons that we haven't quite peered over....Show me Mike, and we will both be rewarded.  |
|
|
|
Post by kc on Apr 15, 2021 16:32:34 GMT -5
MNKD has more than $300M CASH - enough to get to break even.
I heard that they hedged their finances by buying $25 million worth of bitcoin when it was at $45,000 a share.
All will be 👌
|
|
|
|
Post by agedhippie on Apr 27, 2021 10:13:25 GMT -5
... We are very fortunate to have the level of moderators we have, even so the hired folks are welcome here too, as long as they behave (as are we). As I've said, Aged was / is one of my favorite posters, an extremely bright individual in both finance and medicine. Even though I am no match for his intellect, he seemed to enjoy a bit of verbal jousting. ... Now you are making me blush  TBH my interest in Mannkind is chiefly Afrezza. Most of the focus these days is UTHR and that isn't really of interest to me since happily I don't have PAH or similar. If Mannkind decide to get serious about Afrezza and run decent trials then that would change. Right now I feel their focus is elsewhere, and that is fair enough since this is a business after all. |
|
|
|
Post by BD on Apr 27, 2021 10:17:14 GMT -5
I can't believe there are folks "out there" accusing people like aged of being stealth bashers, etc.
It is a kind of crusade of mine to open people's eyes to the fact they do NOT in fact know a basher when they think they see one LOL.
|
|
|
|
Post by cjm18 on Apr 27, 2021 10:26:32 GMT -5
... We are very fortunate to have the level of moderators we have, even so the hired folks are welcome here too, as long as they behave (as are we). As I've said, Aged was / is one of my favorite posters, an extremely bright individual in both finance and medicine. Even though I am no match for his intellect, he seemed to enjoy a bit of verbal jousting. ... Now you are making me blush TBH my interest in Mannkind is chiefly Afrezza. Most of the focus these days is UTHR and that isn't really of interest to me since happily I don't have PAH or similar. If Mannkind decide to get serious about Afrezza and run decent trials then that would change. Right now I feel their focus is elsewhere, and that is fair enough since this is a business after all. Think the peds trial can move the needle at all? |
|
|
|
Post by awesomo on Apr 27, 2021 10:28:19 GMT -5
I can't believe there are folks "out there" accusing people like aged of being stealth bashers, etc. It is a kind of crusade of mine to open people's eyes to the fact they do NOT in fact know a basher when they think they see one LOL. It's pretty much black and white for some people. If you're not all in positive, you're a basher, a short, a stealth basher, a paid shill, etc. There's no room for criticism. |
|
|
|
Post by shawnonafrezza on Apr 27, 2021 10:33:10 GMT -5
Now you are making me blush TBH my interest in Mannkind is chiefly Afrezza. Most of the focus these days is UTHR and that isn't really of interest to me since happily I don't have PAH or similar. If Mannkind decide to get serious about Afrezza and run decent trials then that would change. Right now I feel their focus is elsewhere, and that is fair enough since this is a business after all. Think the peds trial can move the needle at all? Not who you asked, but my $0.02 as another T1. Getting the trial (with good results) won't do much on it's own, they'll have to market it right which means battling the closed loop pumps of which Omnipod will be their biggest hurdle. I'd hate to see marketing on things like Afrezza vs pump on thinks like cake/ice cream because I don't think we should be telling people to really eat those foods too often but that'd be the kind of showing they'd need and if the endos are already saying (and I hate them for this) "just dose for it" then Afrezza clearly wins. |
|
|
|
Post by sayhey24 on Apr 27, 2021 10:33:32 GMT -5
... We are very fortunate to have the level of moderators we have, even so the hired folks are welcome here too, as long as they behave (as are we). As I've said, Aged was / is one of my favorite posters, an extremely bright individual in both finance and medicine. Even though I am no match for his intellect, he seemed to enjoy a bit of verbal jousting. ... Now you are making me blush TBH my interest in Mannkind is chiefly Afrezza. Most of the focus these days is UTHR and that isn't really of interest to me since happily I don't have PAH or similar. If Mannkind decide to get serious about Afrezza and run decent trials then that would change. Right now I feel their focus is elsewhere, and that is fair enough since this is a business after all. Aged - now that we know afrezza does not make your lungs explode maybe you could help out sales and give it a try. Is your endo still concerned about long-term usage? Its been about 6 years. |
|
|
|
Post by agedhippie on Apr 27, 2021 14:22:24 GMT -5
Think the peds trial can move the needle at all? Not who you asked, but my $0.02 as another T1. Getting the trial (with good results) won't do much on it's own, they'll have to market it right which means battling the closed loop pumps of which Omnipod will be their biggest hurdle. I'd hate to see marketing on things like Afrezza vs pump on thinks like cake/ice cream because I don't think we should be telling people to really eat those foods too often but that'd be the kind of showing they'd need and if the endos are already saying (and I hate them for this) "just dose for it" then Afrezza clearly wins. I agree with Shawn. The competition is going to be the closed loop Omnipod system for kids. It has the advantage over tubed pumps of being stuck to the kid with nothing to catch or be pulled, it's a holistic solution (provides both basal and bolus), and the TIR is good. The biggest factor in all of this is that pumps and pediatrics are a known quantity - the endos are in their comfort zone. |
|
